21 results for author:"Widlund H.R." in Literature citations
Results Customize
› Repeat search in UniProtKB (2)
| SOX2 contributes to melanoma cell invasion. Girouard S.D., Laga A.C., Mihm M.C., Scolyer R.A., Thompson J.F., Zhan Q., Widlund H.R., Lee C.W., Murphy G.F. Lab. Invest. 92:362-370(2012) · Mapped (3) |
| Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Feige E., Yokoyama S., Levy C., Khaled M., Igras V., Lin R.J., Lee S., Widlund H.R., Granter S.R., Kung A.L. et al. Proc. Natl. Acad. Sci. U.S.A. 108:E924-33(2011) · Mapped (7) |
| PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Ilic N., Utermark T., Widlund H.R., Roberts T.M. Proc. Natl. Acad. Sci. U.S.A. 108:E699-708(2011) · Mapped (7) |
| VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Frank N.Y., Schatton T., Kim S., Zhan Q., Wilson B.J., Ma J., Saab K.R., Osherov V., Widlund H.R., Gasser M. et al. Cancer Res. 71:1474-1485(2011) · Mapped (15) |
| Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Stewart R.A., Sanda T., Widlund H.R., Zhu S., Swanson K.D., Hurley A.D., Bentires-Alj M., Fisher D.E., Kontaridis M.I., Look A.T. et al. Dev. Cell 18:750-762(2010) · Mapped (10) |
| An oncogenic role for ETV1 in melanoma. Jane-Valbuena J., Widlund H.R., Perner S., Johnson L.A., Dibner A.C., Lin W.M., Baker A.C., Nazarian R.M., Vijayendran K.G., Sellers W.R. et al. Cancer Res. 70:2075-2084(2010) · Mapped (7) |
| GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Scott K.L., Kabbarah O., Liang M.C., Ivanova E., Anagnostou V., Wu J., Dhakal S., Wu M., Chen S., Feinberg T. et al. |
| Imatinib targeting of KIT-mutant oncoprotein in melanoma. Jiang X., Zhou J., Yuen N.K., Corless C.L., Heinrich M.C., Fletcher J.A., Demetri G.D., Widlund H.R., Fisher D.E., Hodi F.S. Clin. Cancer Res. 14:7726-7732(2008) · Mapped (7) |
| Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Yokoyama S., Feige E., Poling L.L., Levy C., Widlund H.R., Khaled M., Kung A.L., Fisher D.E. Pigment Cell Melanoma Res 21:457-463(2008) · Mapped (8) |
| Central role of p53 in the suntan response and pathologic hyperpigmentation. Cui R., Widlund H.R., Feige E., Lin J.Y., Wilensky D.L., Igras V.E., D'Orazio J., Fung C.Y., Schanbacher C.F., Granter S.R. et al. Cell 128:853-864(2007) · Mapped (50) |
| Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Davis I.J., Kim J.J., Ozsolak F., Widlund H.R., Rozenblatt-Rosen O., Granter S.R., Du J., Fletcher J.A., Denny C.T., Lessnick S.L. et al. Cancer Cell 9:473-484(2006) · Mapped (10) |
| Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. Sun T., Hafler B.P., Kaing S., Kitada M., Ligon K.L., Widlund H.R., Yuk D.I., Stiles C.D., Rowitch D.H. Dev. Biol. 292:152-164(2006) · Mapped (29) |
| Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J. et al. Nature 436:117-122(2005) · Mapped (7) |
| Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Du J., Widlund H.R., Horstmann M.A., Ramaswamy S., Ross K., Huber W.E., Nishimura E.K., Golub T.R., Fisher D.E. Cancer Cell 6:565-576(2004) · Mapped (3) |
| Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Miller A.J., Du J., Rowan S., Hershey C.L., Widlund H.R., Fisher D.E. Cancer Res. 64:509-516(2004) · Mapped (34) |
| Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Kenney A.M., Widlund H.R., Rowitch D.H. Development 131:217-228(2004) · Mapped (11) |
| A tissue-restricted cAMP transcriptional response: SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes. Huber W.E., Price E.R., Widlund H.R., Du J., Davis I.J., Wegner M., Fisher D.E. J. Biol. Chem. 278:45224-45230(2003) · Mapped (18) |
| MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Du J., Miller A.J., Widlund H.R., Horstmann M.A., Ramaswamy S., Fisher D.E. Am. J. Pathol. 163:333-343(2003) · Mapped (9) |
| NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Baksh S., Widlund H.R., Frazer-Abel A.A., Du J., Fosmire S., Fisher D.E., DeCaprio J.A., Modiano J.F., Burakoff S.J. Mol. Cell 10:1071-1081(2002) · Mapped (29) |
| Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. Widlund H.R., Horstmann M.A., Price E.R., Cui J., Lessnick S.L., Wu M., He X., Fisher D.E. J. Cell Biol. 158:1079-1087(2002) · Mapped (44) |
| Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. McGill G.G., Horstmann M., Widlund H.R., Du J., Motyckova G., Nishimura E.K., Lin Y.L., Ramaswamy S., Avery W., Ding H.F. et al. Cell 109:707-718(2002) · Mapped (24) |